The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding for HIV prevention efforts.

Gilead Sciences, maker of the drug, announced that a twice-a-year injection of lenacapavir has been approved in the United States for HIV prevention under the brand name Yeztugo.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to prevent HIV—a milestone in the decadeslong fight against a once ...

This collaboration enables Osler to seamlessly integrate selected AI applications into their clinical workflows to enhance workflow efficiencies and improve patient care.

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences GILD.O lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.

New York City became the first city in the country to allow supervised drug use sites where people can use illegal drugs without threat of arrest, under the watch of trained staff, Mayor Bill de ...